Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-10-21 03:01 CEST (UTC+2h)
 

EMA Q&A vs EMA Product Specific guideline [Regulatives / Guidelines]

posted by Averroes - Spain, 2017-10-04 12:01  - Posting: # 17850
Views: 328

Dear all,

I would like to know the opinion of the members of the forum about the following point regarding additional modes of administration stated on EMA Q&A on bioequivalence.

According to EMA Q&A on bioequivalence (point 3.6)here if the SmPC of the reference product allows for the possibility to administer the tablet crushed/disintegrated (and dispersed in food), bioequivalence should also be demonstrated, in principle, for a test product with this additional mode of administration.

This point of the Q&A may be confusing and may clash to what is indicated in the product specific quidelines of some products. An example:

-Ticagrelor: SmPC of Ticagrelor indicates that the tablets can be crushed to a fine powder mixed with 1/2 glass of water and administered. It also allows to administer via nasogastric tube. However the Product specific guideline here ask only for fasting study.

Taking into account that Ticagrelor is not BCS class I or III the question is:
Is it supossed a generic should also test these additional modes of administrations (crushed and nasogastric :confused::surprised:)? or, as indicated in the specific guideline a fasting study would be enough?

I have had not checked all Product Specific guidelines but it's possible there could be some other products with a similar situation.

In my opinion this point of EMA Q&A could be the starting point and opens a Pandora's box on new requirements for generics when additional method of administration is stated in the SmPC of the reference. It seems this may lead that for BCS class II or IV the most sensitive method to detect difference in formularion (i.e. fasting/fed, crushed/whole, ...) is not clear for EMA (may always be formulation-dependent) and they are asking to check everything (like they already did for Tadalafil).

What do you think?

Thanks,

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
17,396 Posts in 3,726 Threads, 1,074 registered users;
25 users online (0 registered, 25 guests).

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed